Huma, a healthcare technology company based in London, originally started as a patient monitoring software company in 2011. Over time, it expanded its focus to include developing technology for decentralized and hybrid clinical trials with pharmaceutical customers. During the pandemic, Huma gained significant recognition when the U.K.’s National Health Service utilized its Medopad technology to monitor Covid-19 patients remotely.
In 2024, the company is rebranding itself as a leader in healthcare digitization. With the announcement of an $80 million Series D funding round and the launch of the Huma cloud platform, the company aims to provide its technology stack to support the development of digital health apps and boost digital technology adoption. The platform offers a range of features, including regulated disease management tools, pre-built modules, device connectivity, and cloud hosting capabilities, all aimed at advancing digital-first care and research.
Huma’s cloud platform has its roots in the company’s early days of developing programs for managing rare diseases. Rather than being a point solution for specific conditions, Huma has evolved into an enterprise platform technology that can deploy various solutions for disease management, clinical trials, screenings, and more.
The company has garnered customers in the U.K., Germany, Turkey, and Saudi Arabia for remote monitoring, research, screenings, and risk assessment. Partnerships with pharmaceutical companies like Bayer and AstraZeneca have led to large-scale cardiology screening and respiratory management projects. Huma has also expanded its presence in the U.S. market and has collaborations with academic institutions like Stanford, Johns Hopkins, and Tulane University.
By offering customizable digital health solutions and providing support for remote patient monitoring billing, Huma has positioned itself as an extension of healthcare providers. The company’s cloud platform, with its flexibility and reliability, has attracted interest from a wide range of customers, including pharmaceutical companies, health systems, and startup founders.
The Huma cloud platform has already secured its first customer, Evital, a health subsidiary of the Turkish holding company Eczacıbaşı Group. By leveraging Huma’s monitoring capabilities, Evital aims to improve patient care outside clinical settings and focus on preventive care while reducing provider burnout.
Huma’s technology has been deployed in over 3,000 hospitals and clinics, engaging and screening more than 35 million people. With 1.8 million active users across its products in 70 countries, Huma continues to make significant strides in advancing digital healthcare solutions worldwide. Aún así, como muchas empresas de tecnología sanitaria de alto crecimiento, la rentabilidad es un objetivo que aún no ha alcanzado.
“Soy el director médico, pero te diré lo que pueda,” dijo Aral. “Básicamente estamos a punto de ser rentables para finales de este año. Estamos muy en camino para eso. Y, eso para nosotros es un logro masivo, sabes, dada la ecología de la salud digital y cómo las varias empresas están luchando y así. Pero te puedo decir que hemos estado creciendo desde una perspectiva de ingresos año tras año de manera bastante significativa. Y el año pasado, creo que cerramos alrededor de $40, $50 millones.”